Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction findings from the EVEREST trial

Robert J. Mentz, Stephen J. Greene, Andrew P. Ambrosy, Muthiah Vaduganathan, Haris P. Subacius, Karl Swedberg, Aldo P. Maggioni, Savina Nodari, Piotr Ponikowski, Stefan D. Anker, Javed Butler, Mihai Gheorghiade

Research output: Contribution to journalArticle

Abstract

Background: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. Methods and Results: An analysis was performed on 3731 (90%) of 4133 hospitalized HF patients with ejection fraction ≤40% enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data, comparing the clinical characteristics and outcomes (all-cause mortality and cardiovascular mortality or HF hospitalization) of patients with and without anemia (hemoglobin 100 days) on adjusted analysis (both P>0.1). Conclusions: Among hospitalized HF patients with reduced ejection fraction, modest anemia at discharge but not baseline was associated with increased all-cause mortality and short-term cardiovascular mortality plus HF hospitalization. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331.

Original languageEnglish
Pages (from-to)401-408
Number of pages8
JournalCirculation: Heart Failure
Volume7
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Patient Discharge
Anemia
Heart Failure
Mortality
Hemoglobins
Hospitalization
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • Anemia
  • Heart failure
  • Hemoglobin
  • Hospitalization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction findings from the EVEREST trial. / Mentz, Robert J.; Greene, Stephen J.; Ambrosy, Andrew P.; Vaduganathan, Muthiah; Subacius, Haris P.; Swedberg, Karl; Maggioni, Aldo P.; Nodari, Savina; Ponikowski, Piotr; Anker, Stefan D.; Butler, Javed; Gheorghiade, Mihai.

In: Circulation: Heart Failure, Vol. 7, No. 3, 2014, p. 401-408.

Research output: Contribution to journalArticle

Mentz, RJ, Greene, SJ, Ambrosy, AP, Vaduganathan, M, Subacius, HP, Swedberg, K, Maggioni, AP, Nodari, S, Ponikowski, P, Anker, SD, Butler, J & Gheorghiade, M 2014, 'Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction findings from the EVEREST trial', Circulation: Heart Failure, vol. 7, no. 3, pp. 401-408. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000840
Mentz, Robert J. ; Greene, Stephen J. ; Ambrosy, Andrew P. ; Vaduganathan, Muthiah ; Subacius, Haris P. ; Swedberg, Karl ; Maggioni, Aldo P. ; Nodari, Savina ; Ponikowski, Piotr ; Anker, Stefan D. ; Butler, Javed ; Gheorghiade, Mihai. / Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction findings from the EVEREST trial. In: Circulation: Heart Failure. 2014 ; Vol. 7, No. 3. pp. 401-408.
@article{f348494a128a4395b9f11e1b078c37cb,
title = "Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction findings from the EVEREST trial",
abstract = "Background: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. Methods and Results: An analysis was performed on 3731 (90{\%}) of 4133 hospitalized HF patients with ejection fraction ≤40{\%} enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data, comparing the clinical characteristics and outcomes (all-cause mortality and cardiovascular mortality or HF hospitalization) of patients with and without anemia (hemoglobin 100 days) on adjusted analysis (both P>0.1). Conclusions: Among hospitalized HF patients with reduced ejection fraction, modest anemia at discharge but not baseline was associated with increased all-cause mortality and short-term cardiovascular mortality plus HF hospitalization. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331.",
keywords = "Anemia, Heart failure, Hemoglobin, Hospitalization",
author = "Mentz, {Robert J.} and Greene, {Stephen J.} and Ambrosy, {Andrew P.} and Muthiah Vaduganathan and Subacius, {Haris P.} and Karl Swedberg and Maggioni, {Aldo P.} and Savina Nodari and Piotr Ponikowski and Anker, {Stefan D.} and Javed Butler and Mihai Gheorghiade",
year = "2014",
doi = "10.1161/CIRCHEARTFAILURE.113.000840",
language = "English",
volume = "7",
pages = "401--408",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction findings from the EVEREST trial

AU - Mentz, Robert J.

AU - Greene, Stephen J.

AU - Ambrosy, Andrew P.

AU - Vaduganathan, Muthiah

AU - Subacius, Haris P.

AU - Swedberg, Karl

AU - Maggioni, Aldo P.

AU - Nodari, Savina

AU - Ponikowski, Piotr

AU - Anker, Stefan D.

AU - Butler, Javed

AU - Gheorghiade, Mihai

PY - 2014

Y1 - 2014

N2 - Background: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. Methods and Results: An analysis was performed on 3731 (90%) of 4133 hospitalized HF patients with ejection fraction ≤40% enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data, comparing the clinical characteristics and outcomes (all-cause mortality and cardiovascular mortality or HF hospitalization) of patients with and without anemia (hemoglobin 100 days) on adjusted analysis (both P>0.1). Conclusions: Among hospitalized HF patients with reduced ejection fraction, modest anemia at discharge but not baseline was associated with increased all-cause mortality and short-term cardiovascular mortality plus HF hospitalization. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331.

AB - Background: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. Methods and Results: An analysis was performed on 3731 (90%) of 4133 hospitalized HF patients with ejection fraction ≤40% enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data, comparing the clinical characteristics and outcomes (all-cause mortality and cardiovascular mortality or HF hospitalization) of patients with and without anemia (hemoglobin 100 days) on adjusted analysis (both P>0.1). Conclusions: Among hospitalized HF patients with reduced ejection fraction, modest anemia at discharge but not baseline was associated with increased all-cause mortality and short-term cardiovascular mortality plus HF hospitalization. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331.

KW - Anemia

KW - Heart failure

KW - Hemoglobin

KW - Hospitalization

UR - http://www.scopus.com/inward/record.url?scp=84902810584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902810584&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.113.000840

DO - 10.1161/CIRCHEARTFAILURE.113.000840

M3 - Article

C2 - 24737459

AN - SCOPUS:84902810584

VL - 7

SP - 401

EP - 408

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 3

ER -